As part of the UM Cancer Network, local hospitals affiliated with the NCI-designated University of Maryland Greenebaum Comprehensive Cancer Center have immediate access to the expertise and innovation taking place at UMGCCC every day - your doorway to something greater, close to home.

Here are some facts that differentiate the UMGCCC:

  • As a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, UMGCCC is in the top tier of the nation's cancer centers.
  • Cancer research funding to UMGCC experts has grown from $19.4 million to $64.2 million in 12 years.
  • UMGCCCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities.
  • Dr. Stuart Martin discovered that "microtentacles" on breast cancer cells play a key role in how cancers spread in the body.
  • UMGCCC is ranked among the top cancer programs in the country according to U.S. News & World Report.
  • UMGCCC is affiliated with the Maryland Proton Treatment Center, which offers a highly advanced and precise form of radiation treatment.
  • Dr. Angela Brodie discovered aromatase inhibitors for the treatment of breast cancer. Recent trials also showed that these drugs can prevent two thirds of cancers in women at high risk for developing the disease. Dr. Brodie and her colleagues have developed a new androgen synthesis inhibitor that shows great promise in treating prostate cancer.
  • Dr. Kevin Cullen's research demonstrated for the first time that racial survival disparities in head and neck cancer are largely explained by previously unknown differences between racial and ethnic groups in the rate of human papillomavirus (HPV) infection.
  • UMGCCC researchers are pioneering stem cell and HIV/AIDS-related cancer studies in partnership with the University of Maryland Center for Stem Cell Biology and Regenerative Medicine and the Institute of Human Virology.